サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：卵巣がん治療薬の世界市場 - 産業規模、シェア、動向、機会、予測：薬剤クラス別、腫瘍タイプ別、流通チャネル別、地域別（2017年～2027年）
市場調査レポート
商品コード
1152252

卵巣がん治療薬の世界市場 - 産業規模、シェア、動向、機会、予測：薬剤クラス別、腫瘍タイプ別、流通チャネル別、地域別（2017年～2027年）

Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Drug Class, By Tumor Type, By Distribution Channel, By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 117 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.95円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

卵巣がん治療薬の世界市場 - 産業規模、シェア、動向、機会、予測：薬剤クラス別、腫瘍タイプ別、流通チャネル別、地域別（2017年～2027年）
出版日: 2022年11月01日
発行: TechSci Research
ページ情報: 英文 117 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の卵巣がん治療薬の市場規模は、予測期間中の2023年～2027年に目覚ましい成長を遂げると予測されています。

卵巣がん治療薬の市場は、近年の卵巣がん患者数の増加により非常に好都合な状況下で成長し、近い将来、先進国において大きな成長を遂げると見込まれます。 また、高齢女性人口率の上昇が、予測期間中の世界の卵巣がん治療薬市場を押し上げる見通しです。さらに、市場企業や様々な研究機関が、卵巣がん治療薬の開発に向けた研究開発活動を活発化させています。

当レポートでは、世界の卵巣がん治療薬市場について調査分析し、セグメント別・地域別の市場規模・シェア予測、市場力学、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 COVID-19が世界の卵巣がん治療薬市場に与える影響

第4章 VOC（顧客の声）

第5章 臨床試験分析

第6章 特許分析

第7章 世界の卵巣がん治療薬市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別（アルキル化剤、有糸分裂阻害剤、抗リウマチ剤、抗乾癬剤、VEGF/VEGFR阻害剤、PARP阻害剤、抗腫瘍剤、その他）
    • 腫瘍タイプ別（上皮性卵巣がん、卵巣低悪性度腫瘍、胚細胞腫瘍、性索間質腫瘍）
    • 流通チャネル別（院内薬局、小売薬局、オンライン薬局）
    • 企業別（2021年）
    • 地域別
  • 市場マップ

第8章 北米の卵巣がん治療薬市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • 腫瘍タイプ別
    • 流通チャネル別
    • 国別
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 欧州の卵巣がん治療薬市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • 腫瘍タイプ別
    • 流通チャネル別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第10章 アジア太平洋の卵巣がん治療薬市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • 腫瘍タイプ別
    • 流通チャネル別
    • 国別
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第11章 南米の卵巣がん治療薬市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • 腫瘍タイプ別
    • 流通チャネル別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第12章 中東・アフリカの卵巣がん治療薬市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • 腫瘍タイプ別
    • 流通チャネル別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第13章 市場力学

  • 促進要因
  • 課題

第14章 市場の動向と開発

第15章 競合情勢

  • AstraZeneca, Plc.
  • GlaxoSmithKline, Plc.
  • Merck & Co.
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Amgen Inc.
  • C.H. Boehringer Sohn Ko. KG
  • Novartis AG

第16章 戦略的提言

目次
Product Code: 12865

The global ovarian cancer drugs market is anticipated to witness an impressive growth during the forecast period, 2023-2027. Ovarian Cancer is one of the most severe and common cancer that affects the women these days. The ovaries in this malignancy undergo irregular cell proliferation, which can invade or negatively impact other body parts like the liver, lymph nodes, intestine and bladder linings, abdominal layers, and lymph nodes. The early stages of ovarian cancer are accompanied by a few indistinct symptoms that become more obvious as the malignancy progresses. These signs include bloating, pelvic pain, abdominal swell, and appetite loss. Ovarian Cancer risk is higher in women who have ovulated more frequently throughout their life, which can also include women who have never given birth and those who started ovulating at a young age. According to the American Cancer Society estimations, the inherited genetic factors contribute to about 10% of occurrences of ovarian cancer. 50% of women who carry BRCA1 or BRCA2 gene mutations will get breast or ovarian cancer. The most frequent type of ovarian cancer, accounting for 95% of occurrences worldwide, is ovarian carcinoma.

Growing Prevalence of Ovarian Cancer

The market for ovarian cancer drugs is growing in a highly favourable environment due to the recent increase in ovarian cancer cases. The American Cancer Society reports that in 2016, there were approximately 22,280 new instances of ovarian cancer diagnosed, resulting in 14,240 fatalities in the United States. Ovarian cancer accounted for 1.3% of the incidence rate and 2.4% of all fatalities attributable to cancer in 2016, according to statistics from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. There will be 23,820 new cases of ovarian cancer recorded in 2020, and the American Cancer Society believes that 1 in 75 women will get ovarian cancer during their lifetimes, with a 1 in 100 risks that she will pass away from it. As of 2017, 1,580 new ovarian cancer cases are anticipated to have been detected, making about 2.5% of all new cancer cases in the nation, according to the Australian Government's Cancer Australia. 1,047 fatalities are anticipated because of this in 2017. Therefore, it is anticipated that the ovarian cancer drugs sector will soon experience significant growth in developed nations.

Increasing Elderly Female Population

The increase in the percentage of the elderly female population is expected to boost the global ovarian cancer drugs market during the forecast period. As the population of old females increases, they are projected to be suffering from more gynecological problems. For instance, according to the World Population Prospects, there were about 9.5% females above the age group of 60 years as of 2021, from which most of the female population are susceptible to gynecological infections or diseases or cancer. Ovarian cancer prevalence is often low in women under the age of 40. Most of the ovarian cancer cases are observed among women 60 years of age and older, according to the American Cancer Society. 7,378 new cases of ovarian cancer were reported in the nation in 2014, with approximately 53% of those cases being identified in women 65 years of age and older, according to Cancer Research UK.

Increasing Research & Development Activities to Develop Ovarian Cancer Drugs

The growing prevalence of ovarian cancer has made the companies operating in the market along with different research organizations to increase their research & development activities in order to develop a potential drug treatment for ovarian cancer. Companies in the pharmaceutical business are increasingly coming up with novel drug combinations to treat ovarian cancer. To treat complex medical diseases, combination medications combine two or more active pharmaceutical ingredients (APIs) into a single dosage form. To lower manufacturing costs, boost compliance and efficiency, enhance medication concordance, increase profitability, and lessen side effects, pharmaceutical companies in the ovarian cancer medications market are investing in the research and development of novel products such as combination drugs. For instance, Roche's well-known tranquilizer Avastin (bevacizumab), which is used to treat advanced stage (III or IV) ovarian cancer, is a combination drug approved by the FDA that contains ingredients like carboplatin and paclitaxel.

Market Segmentation

The global ovarian cancer drugs market is segmented into by drug class, by tumor type, by distribution, by region. Based on by drug class, the market can be fragmented into alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, antineoplastics and others. Based on tumor type, the market can be categorized into epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor. Based on distribution channel, the market can be fragmented into hospital pharmacies, retail pharmacies, online pharmacies. Regionally, North America dominated the market among Europe, Asia Pacific, Middle East & Africa and South America. The United States held the biggest market in North America region and is expected to be a lucrative market in the forecast period as the government is investing in research for new drugs for the easy detection of ovarian cancer for the affected people.

Market Players

AstraZeneca, Plc., GlaxoSmithKline, Plc., Merck & Co., Clovis Oncology, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn Ko. KG, Novartis AG are some of the leading players operating in the global ovarian cancer drugs market.

Report Scope:

In this report, global ovarian cancer drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Ovarian Cancer Drugs Market, By Drug Class:

  • Alkylating Agents
  • Mitotic Inhibitors
  • Antirheumatics
  • Antipsoriatics
  • VEGF/VEGFR Inhibitors
  • PARP Inhibitors
  • Antineoplastics
  • Others

Ovarian Cancer Drugs Market, By Tumor Type:

  • Epithelial Ovarian Cancer
  • Ovarian Low Malignant Potential Tumor
  • Germ Cell Tumor
  • Sex Cord-Stromal Tumor

Ovarian Cancer Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Ovarian Cancer Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global ovarian cancer drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Ovarian Cancer Drugs Market

4. Voice of Customer

5. Clinical Trial Analysis

6. Patent Analysis

7. Global Ovarian Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others)
    • 7.2.2. By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor)
    • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.4. By Company (2021)
    • 7.2.5. By Region
  • 7.3. Market Map

8. North America Ovarian Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Tumor Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Ovarian Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Tumor Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Ovarian Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Tumor Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Ovarian Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Tumor Type
        • 8.3.3.2.3. By Distribution Channel

9. Europe Ovarian Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Tumor Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Ovarian Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Tumor Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Germany Ovarian Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Tumor Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. United Kingdom Ovarian Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Tumor Type
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Italy Ovarian Cancer Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Tumor Type
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Spain Ovarian Cancer Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Tumor Type
        • 9.3.5.2.3. By Distribution Channel

10. Asia-Pacific Ovarian Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Tumor Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Ovarian Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Tumor Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. India Ovarian Cancer Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Tumor Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Japan Ovarian Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Tumor Type
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. South Korea Ovarian Cancer Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Class
        • 10.3.4.2.2. By Tumor Type
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Australia Ovarian Cancer Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Drug Class
        • 10.3.5.2.2. By Tumor Type
        • 10.3.5.2.3. By Distribution Channel

11. South America Ovarian Cancer Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Tumor Type
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Ovarian Cancer Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Tumor Type
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Argentina Ovarian Cancer Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Tumor Type
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. Colombia Ovarian Cancer Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Tumor Type
        • 11.3.3.2.3. By Distribution Channel

12. Middle East and Africa Ovarian Cancer Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Class
    • 12.2.2. By Tumor Type
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Ovarian Cancer Drugs Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Drug Class
        • 12.3.1.2.2. By Tumor Type
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Saudi Arabia Ovarian Cancer Drugs Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Drug Class
        • 12.3.2.2.2. By Tumor Type
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. UAE Ovarian Cancer Drugs Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Drug Class
        • 12.3.3.2.2. By Tumor Type
        • 12.3.3.2.3. By Distribution Channel

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. AstraZeneca, Plc.
  • 15.2. GlaxoSmithKline, Plc.
  • 15.3. Merck & Co.
  • 15.4. Clovis Oncology, Inc.
  • 15.5. F. Hoffmann-La Roche AG
  • 15.6. Bristol-Myers Squibb Co.
  • 15.7. Eli Lilly and Company
  • 15.8. Amgen Inc.
  • 15.9. C.H. Boehringer Sohn Ko. KG
  • 15.10. Novartis AG

16. Strategic Recommendations